Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Martha Mekebeb-Reuter"'
Autor:
Luis Abrishamian, Marc Bonten, Richa Chandra, Damodaran Solai Elango, Pierre Fustier, Kinfemichael Gedif, Susana Goncalves, Awawu Igbinadolor, Jeff Kingsley, Charles G Knutson, Petra Kukkaro, Nagalingeswaran Kumarasamy, Philippe Legenne, Martha Mekebeb-Reuter, Krishnan Ramanathan, Evgeniya Reshetnyak, Michael Robinson, Jennifer Rosa, Marianne Soergel, Vaia Stavropoulou, Nina Stojcheva, Michael T Stumpp, Andreas Tietz, Xiaojun Zhao, Zhaojie Zhang
Publikováno v:
Open Forum Infectious Diseases. 9
Background Ensovibep is a multi-specific DARPin (designed ankyrin repeat protein) antiviral in clinical development for treatment of COVID-19. In the Phase 2 EMPATHY study, ensovibep demonstrated greater viral load decline versus placebo. Here we rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bf0d7915d759c7edfda66906da2a1ac
https://doi.org/10.1093/ofid/ofac492.969
https://doi.org/10.1093/ofid/ofac492.969
Autor:
Lavannya Pandit, Julia Garcia-Diaz, Gerard J. Criner, Benjamin Kramer, Jamie Freedman, Maria F. González-Lara, Rachel Baden, Linda Yau, Jian Han, Shalini V. Mohan, Miriam L Cameron, Reena Shah, Carlos Salama, Victoria Chávez, Martha Mekebeb-Reuter, Ferdinando Lima de Menezes, Jeffrey D. Neidhart, Emma Kaplan-Lewis, W. Reiss, Beverly Assman
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945cc410d68f153659cd71656758fd56
https://doi.org/10.1056/nejmoa2030340
https://doi.org/10.1056/nejmoa2030340
Autor:
Ferdinando Lima de Menezes, W. Reiss, Emma Kaplan-Lewis, Maria F. González-Lara, Beverly Assman, Miriam L. Cameron, Linda Yau, Reena Shah, Gerard J. Criner, Jian Han, Julia Garcia-Diaz, Jamie Freedman, Martha Mekebeb-Reuter, Benjamin Kramer, Rachel Baden, Shalini V. Mohan, Victoria Chávez, Jeffrey D. Neidhart, Lavannya M. Pandit, Carlos Salama
BackgroundCoronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Safety and efficacy of the anti–interleukin-6 receptor antibody tocilizumab was evaluated in patients hospitalized with Covid-19 pneumonia.MethodsNo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4ade2fe46511f13e8cfbe55a0f84968
https://doi.org/10.1101/2020.10.21.20210203
https://doi.org/10.1101/2020.10.21.20210203
